Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Clinical Utility of LIBS Multi-Element Imaging and the IFF Algorithm in Chronic Lung Diseases (PNEUMO-LIBS)

8 september 2026 uppdaterad av: University Hospital, Grenoble

Evaluation of the Clinical Utility of LIBS Multi-Element Imaging and the IFF Algorithm for the Etiological and Medico-Legal Management of Chronic Lung Diseases

PNEUMO-LIBS is a multicenter, non-interventional observational study designed to evaluate whether multi-element tissue imaging by Laser-Induced Breakdown Spectroscopy (LIBS), combined with an artificial intelligence-based analysis tool called Interesting Features Finder (IFF), may help physicians better understand the possible causes of chronic lung diseases.

The study focuses on adult patients with chronic lung diseases for which a lung biopsy has already been performed as part of routine medical care. These diseases include diffuse interstitial lung diseases, pulmonary granulomatoses such as sarcoidosis, and emphysema, especially when an environmental or occupational exposure is suspected but not clearly demonstrated.

Some chronic lung diseases may be influenced by inhaled mineral or metallic particles, such as silica, aluminum, titanium, or other metals. However, these exposures are often difficult to document at the individual patient level. Standard clinical, radiological, and pathological investigations do not usually provide direct information on the presence and distribution of such elements within lung tissue.

LIBS is an imaging technique that can detect and map chemical elements directly in tissue samples, including archived formalin-fixed paraffin-embedded biopsy blocks. In this study, lung biopsy samples will be analyzed with LIBS to search for elemental signatures that may be compatible with occupational or environmental exposures. The IFF algorithm will then be used to help interpret the LIBS data and identify rare or unexpected elemental signals.

The study does not require any additional biopsy, blood test, imaging examination, treatment, or hospital visit for participants. It uses tissue samples and medical data already collected during routine care. The results of LIBS and IFF analyses will be presented to the treating physician or investigator, who will complete standardized online questionnaires at three time points: before receiving the LIBS results, after receiving the LIBS report, and after receiving the IFF-assisted interpretation.

The main objective is to assess the perceived clinical utility of LIBS imaging for physicians, particularly regarding etiological understanding, possible occupational disease recognition, and prevention-oriented reasoning. Secondary objectives include assessing the added value of the IFF algorithm and evaluating the feasibility of a centralized multicenter workflow for sample transfer, LIBS analysis, IFF processing, result reporting, and questionnaire completion.

The study aims to include approximately 70 patients across several French hospital centers. Its results may support the development of future diagnostic, occupational health, and environmental medicine approaches, without modifying the medical care of participants during the study.

Studieöversikt

Status

Rekrytering

Betingelser

Studietyp

Observationell

Inskrivning (Beräknad)

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Namn: Benoit BUSSER
Telefonnummer: +33476768939
E-post: BBusser@chu-grenoble.fr

Studera Kontakt Backup

Namn: Vincent BONNETERRE
Telefonnummer: +33476765851
E-post: VBonneterre@chu-grenoble.fr

Studieorter

Frankrike
- - Grenoble, Frankrike
    - Rekrytering
    - CHU Grenoble Alpes
    - Kontakt:
      
      Benoit BUSSER
      
      Telefonnummer: +33476768939
      
      E-post: BBusser@chu-grenoble.fr
    - Kontakt:
      
      Vincent BONNETERRE
      
      Telefonnummer: 33+ (0)4 76 76 58 51
      
      E-post: VBonneterre@chu-grenoble.fr
  - Nancy, Frankrike
    - Rekrytering
    - Centre Hospitalier Régional Universitaire Nancy (CHRU)
    - Kontakt:
      
      Isabelle THAON
      
      Telefonnummer: 33 3 83 15 71 71
      
      E-post: i.thaon@chru-nancy.fr
    - Huvudutredare:
      
      Isabelle THAON
  - Rouen, Frankrike
    - Rekrytering
    - centre Hospitalier Universitaire Rouen (CHU)
    - Kontakt:
      
      Antoine GISLARD
      
      Telefonnummer: 33 2 35 88 82 69
      
      E-post: Antoine.Gislard@chu-rouen.fr
    - Huvudutredare:
      
      Antoine GISLARD

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

Vuxen
Äldre vuxen

Tar emot friska volontärer

Nej

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Adult patients with chronic lung diseases, including interstitial lung diseases, pulmonary granulomatoses such as sarcoidosis, and pulmonary emphysema, for whom a lung biopsy sample obtained during routine care is available for LIBS and IFF analysis. Participants may be identified retrospectively or prospectively in participating French hospital centers. Only patients who have not objected to the use of their health data and biological samples for research will be included.

Beskrivning

Inclusion Criteria:

Adult patient aged 18 years or older.
Diagnosis or documented clinical suspicion of chronic lung disease, including interstitial lung disease, pulmonary granulomatosis such as sarcoidosis, or pulmonary emphysema.
Availability of a lung tissue biopsy sample obtained during routine medical care and stored as a formalin-fixed paraffin-embedded sample.
Sufficient medical record information to document the clinical context, occupational or environmental exposure history, smoking status, imaging, pathology reports, and other relevant routine-care data.
No documented objection to the secondary use of health data and biological samples for this research.

Exclusion Criteria:

Documented objection to participation in the study or to the secondary use of health data or biological samples for research.
Missing, unavailable, degraded, or technically unusable biopsy sample.
Insufficient medical record information to document the clinical context or exposure history.
Lung condition outside the scope of the study, such as isolated acute infection, isolated cardiac disease, or primary lung cancer.
Patient under legal protection when the applicable legal conditions for non-opposition cannot be fulfilled.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Vad mäter studien?

Primära resultatmått

Resultatmått	Åtgärdsbeskrivning	Tidsram
Proportion of Patients With Perceived Added Clinical Value of LIBS Imaging Tidsram: After Review of the LIBS Report, Up to 1 Month After Inclusion	Proportion of patients for whom the investigator reports that LIBS imaging provides new and clinically useful information in at least one of the following domains: etiological understanding, medico-legal reasoning regarding possible occupational disease recognition, or prevention-oriented recommendations.	After Review of the LIBS Report, Up to 1 Month After Inclusion

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

University Hospital, Grenoble

Utredare

Huvudutredare: Vincent BONNETERRE, CHU Grenoble Alpes

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 oktober 2026

Primärt slutförande (Beräknad)

1 juni 2027

Avslutad studie (Beräknad)

1 juli 2027

Studieregistreringsdatum

Först inskickad

12 maj 2026

Först inskickad som uppfyllde QC-kriterierna